AlloVir IPO

AlloVir is a biotechnology specializing in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Total Funding to Date$154.35MM
Register for Details

For more details on financing and valuation for AlloVir, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in